Management of BCG non-responders with fixed dose intravesical gemcitabine in superficial transitional cell carcinoma of urinary bladder | Zendy

NK Mohanty | Zendy; RajibaL Nayak | Zendy; Pawan Vasudeva | Zendy; RP Arora | Zendy

Open Access

Management of BCG non-responders with fixed dose intravesical gemcitabine in superficial transitional cell carcinoma of urinary bladder

Author(s) -

NK Mohanty,

RajibaL Nayak,

Pawan Vasudeva,

RP Arora

Publication year - 2008

Publication title -

indian journal of urology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.333

H-Index - 30

eISSN - 1998-3824

pISSN - 0970-1591

DOI - 10.4103/0970-1591.35759

Subject(s) - medicine , gemcitabine , tolerability , adverse effect , malignancy , urology , transitional cell carcinoma , surgery , incidence (geometry) , chemotherapy , bladder cancer , cancer , physics , optics

The incidence of bladder malignancy is increasing worldwide and the projected rise is 28% by 2010 for both sexes (WHO). Though intravesical adjuvant therapy with BCG is superior to any other immunotherapeutic/chemotherapeutic agent in reducing tumor recurrences and disease progression, its real efficacy remains controversial as one-third of the patients will soon become BCG failure. Hence there is a need for an alternative intravesical agent for treatment of BCG failure. Our aim was to study the efficacy, tolerability and safety of intravesical Gemcitabine in managing BCG-refractory superficial bladder malignancy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research